vs
AdvanSix Inc.（ASIX）与GE医疗（CCRN）财务数据对比。点击上方公司名可切换其他公司
AdvanSix Inc.的季度营收约是GE医疗的1.5倍（$359.9M vs $236.8M），AdvanSix Inc.净利率更高（-0.8% vs -35.0%，领先34.3%），AdvanSix Inc.同比增速更快（9.4% vs -23.6%），AdvanSix Inc.自由现金流更多（$36.1M vs $16.1M），过去两年AdvanSix Inc.的营收复合增速更高（3.4% vs -21.0%）
AdvanSix Inc.是一家美国化工企业，主营尼龙6以及己内酰胺、硫酸铵肥料等相关化工产品。该公司原为霍尼韦尔旗下树脂与化工事业部，于2016年分拆独立，2019年预估营收达14亿美元，其企业历史可追溯至1884年在宾夕法尼亚州法兰克福成立的H. W. Jayne公司。
GE医疗是总部位于美国伊利诺伊州芝加哥的医疗科技企业，品牌标识为GE HealthCare。公司主要业务分为四大板块：包含分子影像、CT、磁共振、妇科筛查及X光设备的医学影像业务、超声业务，以及聚焦远程患者监测、麻醉呼吸护理、心脏诊断、婴幼儿护理的患者护理解决方案业务，此外还开展医药相关业务。
ASIX vs CCRN — 直观对比
营收规模更大
ASIX
是对方的1.5倍
$236.8M
营收增速更快
ASIX
高出33.0%
-23.6%
净利率更高
ASIX
高出34.3%
-35.0%
自由现金流更多
ASIX
多$20.0M
$16.1M
两年增速更快
ASIX
近两年复合增速
-21.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $359.9M | $236.8M |
| 净利润 | $-2.8M | $-82.9M |
| 毛利率 | 7.6% | — |
| 营业利润率 | -0.7% | -30.2% |
| 净利率 | -0.8% | -35.0% |
| 营收同比 | 9.4% | -23.6% |
| 净利润同比 | -892.9% | -2109.7% |
| 每股收益（稀释后） | $-0.11 | $-2.56 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASIXCCRN
| Q4 25 | $359.9M | $236.8M | ||
| Q3 25 | $374.5M | $250.1M | ||
| Q2 25 | $410.0M | $274.1M | ||
| Q1 25 | $377.8M | $293.4M | ||
| Q4 24 | $329.1M | $309.9M | ||
| Q3 24 | $398.2M | $315.1M | ||
| Q2 24 | $453.5M | $339.8M | ||
| Q1 24 | $336.8M | $379.2M |
净利润ASIXCCRN
| Q4 25 | $-2.8M | $-82.9M | ||
| Q3 25 | $-2.6M | $-4.8M | ||
| Q2 25 | $31.4M | $-6.7M | ||
| Q1 25 | $23.3M | $-490.0K | ||
| Q4 24 | $352.0K | $-3.8M | ||
| Q3 24 | $22.3M | $2.6M | ||
| Q2 24 | $38.9M | $-16.1M | ||
| Q1 24 | $-17.4M | $2.7M |
毛利率ASIXCCRN
| Q4 25 | 7.6% | — | ||
| Q3 25 | 6.8% | 20.4% | ||
| Q2 25 | 14.3% | 20.4% | ||
| Q1 25 | 14.2% | 20.0% | ||
| Q4 24 | 3.4% | — | ||
| Q3 24 | 14.4% | 20.4% | ||
| Q2 24 | 17.9% | 20.8% | ||
| Q1 24 | 0.9% | 20.4% |
营业利润率ASIXCCRN
| Q4 25 | -0.7% | -30.2% | ||
| Q3 25 | -0.9% | -2.4% | ||
| Q2 25 | 7.7% | -2.1% | ||
| Q1 25 | 7.7% | -0.3% | ||
| Q4 24 | -3.9% | -1.1% | ||
| Q3 24 | 7.5% | 0.9% | ||
| Q2 24 | 11.5% | -5.7% | ||
| Q1 24 | -7.0% | 0.8% |
净利率ASIXCCRN
| Q4 25 | -0.8% | -35.0% | ||
| Q3 25 | -0.7% | -1.9% | ||
| Q2 25 | 7.7% | -2.4% | ||
| Q1 25 | 6.2% | -0.2% | ||
| Q4 24 | 0.1% | -1.2% | ||
| Q3 24 | 5.6% | 0.8% | ||
| Q2 24 | 8.6% | -4.7% | ||
| Q1 24 | -5.2% | 0.7% |
每股收益（稀释后）ASIXCCRN
| Q4 25 | $-0.11 | $-2.56 | ||
| Q3 25 | $-0.10 | $-0.15 | ||
| Q2 25 | $1.15 | $-0.20 | ||
| Q1 25 | $0.86 | $-0.02 | ||
| Q4 24 | $0.02 | $-0.13 | ||
| Q3 24 | $0.82 | $0.08 | ||
| Q2 24 | $1.43 | $-0.47 | ||
| Q1 24 | $-0.65 | $0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.8M | $108.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $815.2M | $322.8M |
| 总资产 | $1.7B | $449.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASIXCCRN
| Q4 25 | $19.8M | $108.7M | ||
| Q3 25 | $23.7M | $99.1M | ||
| Q2 25 | $18.4M | $81.2M | ||
| Q1 25 | $8.3M | $80.7M | ||
| Q4 24 | $19.6M | $81.6M | ||
| Q3 24 | $17.3M | $64.0M | ||
| Q2 24 | $12.1M | $69.6M | ||
| Q1 24 | $20.6M | $5.2M |
股东权益ASIXCCRN
| Q4 25 | $815.2M | $322.8M | ||
| Q3 25 | $818.2M | $408.1M | ||
| Q2 25 | $823.7M | $412.2M | ||
| Q1 25 | $794.4M | $418.2M | ||
| Q4 24 | $774.6M | $419.0M | ||
| Q3 24 | $766.4M | $424.7M | ||
| Q2 24 | $746.6M | $433.3M | ||
| Q1 24 | $713.2M | $462.4M |
总资产ASIXCCRN
| Q4 25 | $1.7B | $449.0M | ||
| Q3 25 | $1.7B | $538.2M | ||
| Q2 25 | $1.6B | $553.8M | ||
| Q1 25 | $1.6B | $576.2M | ||
| Q4 24 | $1.6B | $589.3M | ||
| Q3 24 | $1.5B | $597.4M | ||
| Q2 24 | $1.5B | $602.9M | ||
| Q1 24 | $1.5B | $648.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $63.7M | $18.2M |
| 自由现金流经营现金流 - 资本支出 | $36.1M | $16.1M |
| 自由现金流率自由现金流/营收 | 10.0% | 6.8% |
| 资本支出强度资本支出/营收 | 7.7% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $6.4M | $40.1M |
8季度趋势，按日历期对齐
经营现金流ASIXCCRN
| Q4 25 | $63.7M | $18.2M | ||
| Q3 25 | $26.6M | $20.1M | ||
| Q2 25 | $21.1M | $4.2M | ||
| Q1 25 | $11.4M | $5.7M | ||
| Q4 24 | $64.2M | $24.2M | ||
| Q3 24 | $57.3M | $7.5M | ||
| Q2 24 | $50.2M | $82.4M | ||
| Q1 24 | $-36.2M | $6.0M |
自由现金流ASIXCCRN
| Q4 25 | $36.1M | $16.1M | ||
| Q3 25 | $66.0K | $17.9M | ||
| Q2 25 | $-7.2M | $2.3M | ||
| Q1 25 | $-22.6M | $3.8M | ||
| Q4 24 | $29.8M | $21.7M | ||
| Q3 24 | $26.8M | $6.3M | ||
| Q2 24 | $16.7M | $79.6M | ||
| Q1 24 | $-71.6M | $3.8M |
自由现金流率ASIXCCRN
| Q4 25 | 10.0% | 6.8% | ||
| Q3 25 | 0.0% | 7.2% | ||
| Q2 25 | -1.7% | 0.8% | ||
| Q1 25 | -6.0% | 1.3% | ||
| Q4 24 | 9.1% | 7.0% | ||
| Q3 24 | 6.7% | 2.0% | ||
| Q2 24 | 3.7% | 23.4% | ||
| Q1 24 | -21.3% | 1.0% |
资本支出强度ASIXCCRN
| Q4 25 | 7.7% | 0.9% | ||
| Q3 25 | 7.1% | 0.9% | ||
| Q2 25 | 6.9% | 0.7% | ||
| Q1 25 | 9.0% | 0.6% | ||
| Q4 24 | 10.4% | 0.8% | ||
| Q3 24 | 7.7% | 0.4% | ||
| Q2 24 | 7.4% | 0.8% | ||
| Q1 24 | 10.5% | 0.6% |
现金转化率ASIXCCRN
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.67× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 182.29× | — | ||
| Q3 24 | 2.57× | 2.92× | ||
| Q2 24 | 1.29× | — | ||
| Q1 24 | — | 2.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASIX
| Plant Nutrients | $140.0M | 39% |
| Chemical Intermediates | $92.8M | 26% |
| Caprolactam | $64.4M | 18% |
| Nylon Resins | $62.8M | 17% |
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
